CURIS Business Summary

Curis Inc. (CRIS) is a clinical-stage biotechnology company that generates revenue primarily through strategic collaboration and licensing agreements, most notably receiving royalties from Genentech (a member of the Roche Group) for Erivedge®, a first-in-class treatment for advanced basal cell carcinoma. The company’s primary business segments are focused on immuno-oncology and precision oncology, with a pipeline centered on its lead asset, emavusertib (CA-4948), an oral small-molecule inhibitor of IRAK4 and FLT3. Curis operates as a high-upside, small-cap developer in the targeted cancer therapy space, competing directly with firms such as Bolt Biotherapeutics, CASI Pharmaceuticals, and Longeveron. While it remains in a pre-profitability phase characterized by significant R&D investment, Curis distinguishes itself through its dual-pathway blockade strategy and a recent $80.8 million PIPE financing secured in early 2026 to fund late-stage clinical trials. Curis was established in 2000 through the strategic merger of Creative BioMolecules, Ontogeny, and Reprogenesis. The current leadership team is headed by President and CEO James E. Dentzer, who brings over 25 years of industry experience from executive roles at Biogen, Dicerna Pharmaceuticals, and Amicus Therapeutics. He is supported by Chief Financial Officer Diantha Duvall, a CPA with extensive experience in life sciences finance, and Chief Scientific Officer Dr. Robert Martell, an oncologist with a deep pedigree in drug development. The company’s strategic direction is overseen by Chairman Martyn Greenacre, a veteran of SmithKline Beecham, and a board that includes prominent industry figures like Dr. John Hohneker. Notable institutional backing includes significant positions held by Armistice Capital, Bleichroeder LP, and M28 Capital Management.